Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Weight between 50 and 125 kg
Mild, stable allergic asthma
History of episodic wheeze and shortness of breath
FEV1 at baseline ≥ 70% of the predicted value
For women of childbearing potential, agreement to use an effective means of contraception while enrolled in the study
For men with partners of childbearing potential, willingness to use condoms with spermicide during treatment
Ability to comprehend and follow all required study procedures
Positive skin prick test to common aeroallergens (e.g., cat, dust, mite, grass, and pollen)
Positive allergen-induced early and late airway bronchoconstriction
You may not be if
A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry
Acute infection (including viral infection) within the 6 weeks preceding dosing (8 weeks for respiratory infections) or any ongoing chronic infection
History of recurrent bacterial infection as an adult or history or presence of any chronic infectious condition, including (but not limited to), tuberculosis, parasitic infection, etc.
Lung disease other than mild allergic asthma
History of heart, lung, kidney, liver, neurologic or chronic infectious disease
Concomitant disease or condition, which could interfere with the conduct of the study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease
History of serious adverse reaction or hypersensitivity to any drug
Pregnancy or lactation or positive serum pregnancy test at screening
Chronic use of any other medication for treatment of allergic lung disease other than short-acting β2-agonists or ipratropium bromide
Current (or history of) treatment with a monoclonal antibody or chimeric biomolecule within the past 5 months (5 half-lives of the drug), including omalizumab
Regular use of tobacco products of any kind or within the previous 6 months, or smoking history \> 10 pack-years
Clareo Health | A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
